폐암환자의 Irinotecan과 Cisplatin 복합화학요법에 있어서 투여방법에 따른 혈액학적 부작용의 차이 연구

Abstract

Combination chemotherapy of irinotecan and cisplatin is a promising treatment in lung cancer. The purpose of this study is to evaluate hematologic toxicities under different two regimens. In addition, effects of supportive drugs on recovery from side effects were evaluated. In IP-IP group, patients received 80 mg/m2 of irinotecan(I) and 40 mg/m2 of cisplatin(P) on day 1 and day 8. In IP-I group, patients received 80 mg/m2 of I and 60 mg/m2 of P on day 1, and 80 mg/m2 of I on day 8. On third week, there was no administration of chemotherapy in both groups. These regimens were treated for 3week interval. Grade 3~4 hematologic toxicities were evaluated in term of number of patients or cycles. Effects of rhEpo and rG-CSF on the rate of recovery from side effects with respect to administration period were assessed. In analysis of patients, anemia, neutropenia and thrombocytopenia showed difference with statistical significance (p=0.002, p＜0.001, p=0.0438). In analysis of cycles, anemia and neutropenia showed the significant difference (p＜0.001, p＜0.001). In analysis of rhEpo effect, the hemoglobin level was increased significantly in both group after the 4th week (p=0.004). With respect to rG-CSF effect, significant increase of ANC was observed after day 7 in IP-IP group (p=0.0430), and after day 1 in IP-I group. The regimen of IP-I group showed lower toxicity profile than that of IP-IP group in combination chemotherapy of irinotecan and cisplatin in lung cancer. The toxicities were effectively recovered by administering supportive drugs.